[Source: F1000 Research, full page: (LINK). Abstract, edited.]
Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance’s 2018 Vaccine Investment Strategy: report from an expert survey
[version 1; peer review: 2 approved]
Maya Malarski 1, Mateusz Hasso-Agopsowicz 2, Adam Soble 3, Wilson Mok 1, Sophie Mathewson 1, Johan Vekemans 2
Author details: 1 Policy, Vaccines & Sustainability, Gavi, the Vaccine Alliance, Le Grand-Saconnex, 1218, Switzerland; 2 Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, 1211, Switzerland; 3 Vaccine Supply & Demand, Vaccines & Sustainability, Gavi, the Vaccine Alliance, Le Grand-Saconnex, 1218, Switzerland
While the rise of antimicrobial resistance (AMR) has been recognised as a major public health problem, the value of vaccines to control AMR is poorly defined. This expert survey was launched with the aim of informing the 2018 Vaccine Investment Strategy through which Gavi, the Vaccine Alliance prioritises future vaccine funding. This exercise focused on both vaccines currently supported by Gavi and under consideration for future funding.
The relative importance of pre-defined criteria as drivers of overall value of vaccines as a tool/ intervention to control AMR was assessed by 18 experts: prevention of mortality and morbidity due to resistant pathogens, antibiotic use prevented, societal impact, ethical importance and sense of urgency. For each vaccine, experts attributed scores reflecting the estimated value for each criterion, and overall value relative to AMR was derived from the value assigned to each criterion and their relative importance for each vaccine.
Mortality, morbidity due to targeted resistant pathogens, and antibiotic use prevented were considered the most important determinants of overall value. Pneumococcal, typhoid and malaria vaccines were assigned highest value relative to antimicrobial resistance. Intermediate value was estimated for specific rotavirus, cholera, respiratory syncytial virus (RSV), influenza, dengue, measles, meningitis and Haemophilus influenza type b- (Hib-) containing pentavalent vaccines. Lowest value relative to AMR was estimated for Japanese encephalitis, hepatitis A, yellow fever, rabies and human papilloma virus vaccine.
In the future, more evidence-based, data-driven, robust methodologies should be developed to guide coordinated, rational decision making on priority actions aimed at strengthening the use of vaccines against AMR.
Keywords: Vaccines, antimicrobial resistance
Corresponding author: Johan Vekemans
Competing interests: No competing interests were disclosed.
Grant information: The author(s) declared that no grants were involved in supporting this work.
Copyright: © 2019 World Health Organisation. This is an open access article distributed under the terms of the Creative Commons Attribution IGO License, which permits copying, adaptation and distribution in any medium or format for any purpose, provided the original work is properly cited, a link is provided to the license, and any changes made are indicated. Any such copying, adaptation and distribution must not in any way suggest that World Health Organisation endorses you or your use.
How to cite: Malarski M, Hasso-Agopsowicz M, Soble A et al. Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance’s 2018 Vaccine Investment Strategy: report from an expert survey [version 1; peer review: 2 approved]. F1000Research 2019, 8:1685 (https://doi.org/10.12688/f1000research.20100.1)
First published: 24 Sep 2019, 8:1685 (https://doi.org/10.12688/f1000research.20100.1)
Latest published: 24 Sep 2019, 8:1685 (https://doi.org/10.12688/f1000research.20100.1)
Keywords: Antibiotics; Drugs Resistance; Vaccines.